Malignancies clinical trials at University of California Health
4 in progress, 2 open to eligible people
Extension Study for Patients Previously Enrolled in Studies with Pelabresib
open to eligible people ages 18 years and up
The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studies
at UCLA
AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
open to eligible people ages 18 years and up
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.
at UCLA
9-ING-41 in Patients with Advanced Cancers
Sorry, in progress, not accepting new patients
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
at UC Irvine UCSF
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Sorry, in progress, not accepting new patients
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
at UCLA
Our lead scientists for Malignancies research studies include Gary J. Schiller, MD Zev A. Wainberg, MD Deborah J. Wong, MD, PhD.
Last updated: